Order a peptide or a compounded shot from a slick telehealth site, and the marketing may outrun the law. In 2026, enforcement is sharpening against online platforms making unlawful drug claims.
In 2026, regulators are increasing scrutiny of gray-market vendors and telehealth platforms making unlawful drug claims, including for peptides and compounded products sometimes marketed as non-FDA medications. The phrase signals products that are not FDA-approved but offered anyway, a framing that can obscure real risks and regulatory limits for consumers.
Telehealth has made it easier than ever to order injectables and peptides with a few taps.
It has also created fertile ground for marketing that outpaces the rules.
Commentary across 2026, including in May, flagged increasing enforcement against gray-market vendors and some telehealth platforms making unlawful drug claims, particularly around peptides and compounded products. In integrative and concierge settings, clinicians sometimes use the shorthand non-FDA medications to describe products that are not FDA-approved but are offered anyway under a wellness framework. That framing can blur an important line: not FDA-approved means a product has not been reviewed for safety, effectiveness, and quality.
The pattern connects the GLP-1 and peptide stories. As compounded GLP-1 access narrows and peptides sit in a regulatory gray zone, online platforms have marketed alternatives aggressively, sometimes with health claims that exceed what the law permits for unapproved products. Regulators have signaled this as an enforcement priority, alongside scrutiny of how such products are sold and described.
For consumers, polished telehealth marketing can lend unwarranted legitimacy to unapproved products. A professional website and a quick questionnaire do not equal FDA review or assured quality. The non-FDA medication label is a flag, not a feature: it indicates a product outside the approval system. Patients are best served by understanding exactly what they are being offered, whether it is FDA-approved, and what the evidence and risks are.
Watch for enforcement actions against platforms making unlawful claims and for clearer guidance on marketing unapproved or compounded products. The interplay with GLP-1 and peptide policy will keep this area active. For consumers, the practical safeguards are to ask whether a product is FDA-approved, to be skeptical of bold health claims for unapproved compounds, and to seek care from licensed clinicians who disclose a products regulatory status rather than obscuring it.